Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors
Neal Ian Lindeman, Philip T. Cagle, Dara L. Aisner et al. · Journal of Thoracic Oncology · 2018
Cited by 645 works. doi:10.1016/j.jtho.2017.12.001 Open-access PDF
Authors
- Neal Ian Lindeman
- Philip T. Cagle
- Dara L. Aisner
- Maria E. Arcila
- Mary Beth Beasley
- Eric Bernicker
- Carol Colasacco
- Sanja Đačić
- Fred R. Hirsch
- Keith M. Kerr
- David J. Kwiatkowski
- Marc Ladanyi
- Jan A. Nowak
- Lynette Marie Sholl
- Robyn Temple‐Smolkin
- Benjamin Solomon
- Lesley Souter
- Erik Thunnissen
- Ming‐Sound Tsao
- Christina B. Ventura
References
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- GRADE guidelines: 3. Rating the quality of evidence
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies